Copyright Reports & Markets. All rights reserved.

Global Human Combination Vaccines Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Human Combination Vaccines Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Human Combination Vaccines Market Size Growth Rate by Product
      • 1.4.2 Human Combination Inactivated Vaccines
      • 1.4.3 Human Combination Live Attenuated Vaccines
    • 1.5 Market by End User
      • 1.5.1 Global Human Combination Vaccines Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Human Combination Vaccines Market Size
      • 2.1.1 Global Human Combination Vaccines Revenue 2014-2025
      • 2.1.2 Global Human Combination Vaccines Sales 2014-2025
    • 2.2 Human Combination Vaccines Growth Rate by Regions
      • 2.2.1 Global Human Combination Vaccines Sales by Regions
      • 2.2.2 Global Human Combination Vaccines Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Human Combination Vaccines Sales by Manufacturers
      • 3.1.1 Human Combination Vaccines Sales by Manufacturers
      • 3.1.2 Human Combination Vaccines Sales Market Share by Manufacturers
      • 3.1.3 Global Human Combination Vaccines Market Concentration Ratio (CR5 and HHI)
    • 3.2 Human Combination Vaccines Revenue by Manufacturers
      • 3.2.1 Human Combination Vaccines Revenue by Manufacturers (2014-2019)
      • 3.2.2 Human Combination Vaccines Revenue Share by Manufacturers (2014-2019)
    • 3.3 Human Combination Vaccines Price by Manufacturers
    • 3.4 Human Combination Vaccines Manufacturing Base Distribution, Product Types
      • 3.4.1 Human Combination Vaccines Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Human Combination Vaccines Product Type
      • 3.4.3 Date of International Manufacturers Enter into Human Combination Vaccines Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Human Combination Vaccines Sales by Product
    • 4.2 Global Human Combination Vaccines Revenue by Product
    • 4.3 Human Combination Vaccines Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Human Combination Vaccines Breakdown Data by End User

    6 North America

    • 6.1 North America Human Combination Vaccines by Countries
      • 6.1.1 North America Human Combination Vaccines Sales by Countries
      • 6.1.2 North America Human Combination Vaccines Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Human Combination Vaccines by Product
    • 6.3 North America Human Combination Vaccines by End User

    7 Europe

    • 7.1 Europe Human Combination Vaccines by Countries
      • 7.1.1 Europe Human Combination Vaccines Sales by Countries
      • 7.1.2 Europe Human Combination Vaccines Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Human Combination Vaccines by Product
    • 7.3 Europe Human Combination Vaccines by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Human Combination Vaccines by Countries
      • 8.1.1 Asia Pacific Human Combination Vaccines Sales by Countries
      • 8.1.2 Asia Pacific Human Combination Vaccines Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Human Combination Vaccines by Product
    • 8.3 Asia Pacific Human Combination Vaccines by End User

    9 Central & South America

    • 9.1 Central & South America Human Combination Vaccines by Countries
      • 9.1.1 Central & South America Human Combination Vaccines Sales by Countries
      • 9.1.2 Central & South America Human Combination Vaccines Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Human Combination Vaccines by Product
    • 9.3 Central & South America Human Combination Vaccines by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Human Combination Vaccines by Countries
      • 10.1.1 Middle East and Africa Human Combination Vaccines Sales by Countries
      • 10.1.2 Middle East and Africa Human Combination Vaccines Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Human Combination Vaccines by Product
    • 10.3 Middle East and Africa Human Combination Vaccines by End User

    11 Company Profiles

    • 11.1 GlaxoSmithKline
      • 11.1.1 GlaxoSmithKline Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 GlaxoSmithKline Human Combination Vaccines Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 GlaxoSmithKline Human Combination Vaccines Products Offered
      • 11.1.5 GlaxoSmithKline Recent Development
    • 11.2 Merck
      • 11.2.1 Merck Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Merck Human Combination Vaccines Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Merck Human Combination Vaccines Products Offered
      • 11.2.5 Merck Recent Development
    • 11.3 Sanofi
      • 11.3.1 Sanofi Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Sanofi Human Combination Vaccines Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Sanofi Human Combination Vaccines Products Offered
      • 11.3.5 Sanofi Recent Development
    • 11.4 Daiichi Sankyo
      • 11.4.1 Daiichi Sankyo Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Daiichi Sankyo Human Combination Vaccines Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Daiichi Sankyo Human Combination Vaccines Products Offered
      • 11.4.5 Daiichi Sankyo Recent Development
    • 11.5 Serum Institute of India
      • 11.5.1 Serum Institute of India Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Serum Institute of India Human Combination Vaccines Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Serum Institute of India Human Combination Vaccines Products Offered
      • 11.5.5 Serum Institute of India Recent Development
    • 11.6 Takeda Pharmaceuticals
      • 11.6.1 Takeda Pharmaceuticals Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Takeda Pharmaceuticals Human Combination Vaccines Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Takeda Pharmaceuticals Human Combination Vaccines Products Offered
      • 11.6.5 Takeda Pharmaceuticals Recent Development

    12 Future Forecast

    • 12.1 Human Combination Vaccines Market Forecast by Regions
      • 12.1.1 Global Human Combination Vaccines Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Human Combination Vaccines Revenue Forecast by Regions 2019-2025
    • 12.2 Human Combination Vaccines Market Forecast by Product
      • 12.2.1 Global Human Combination Vaccines Sales Forecast by Product 2019-2025
      • 12.2.2 Global Human Combination Vaccines Revenue Forecast by Product 2019-2025
    • 12.3 Human Combination Vaccines Market Forecast by End User
    • 12.4 North America Human Combination Vaccines Forecast
    • 12.5 Europe Human Combination Vaccines Forecast
    • 12.6 Asia Pacific Human Combination Vaccines Forecast
    • 12.7 Central & South America Human Combination Vaccines Forecast
    • 12.8 Middle East and Africa Human Combination Vaccines Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Human Combination Vaccines Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      A combination vaccine is designed to provide protection against two or more diseases or against single disease caused by completely different or similar organism. A combination vaccine also boosts the immune system to fight against infection. These vaccines contain two or more antigens that are either combined in ready form or mixed before administration. Safety, efficacy, and immunogenicity of a combined immunizing agent are high.
      The increase in pediatric population is one of the primary growth factors for this market. With the increase in pediatric population, the demand for combination vaccines for immunization is higher as newborn infants are more vulnerable to various infectious diseases due to weak immune systems. These vaccines help reduce the number of shots and healthcare center visits, which consequently save time and money. It has been observed that the occurrence of viral infections and diseases such as polio, tetanus, diphtheria, smallpox, chickenpox, and measles is high among children in developing nations.
      The Americas is expected to be the major revenue contributor to the market by 2023. The introduction of strict regulatory norms that recommend proper vaccination of infants and the continuous efforts by vendors and national organizations to promote the use of human combination vaccines, will drive the market’s growth prospects in the Americas.
      The global Human Combination Vaccines market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Human Combination Vaccines market based on company, product type, end user and key regions.

      This report studies the global market size of Human Combination Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Human Combination Vaccines in these regions.
      This research report categorizes the global Human Combination Vaccines market by top players/brands, region, type and end user. This report also studies the global Human Combination Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      GlaxoSmithKline
      Merck
      Sanofi
      Daiichi Sankyo
      Serum Institute of India
      Takeda Pharmaceuticals

      Market size by Product
      Human Combination Inactivated Vaccines
      Human Combination Live Attenuated Vaccines
      Market size by End User
      Hospitals
      Clinics
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Human Combination Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Human Combination Vaccines market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Human Combination Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Human Combination Vaccines submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Human Combination Vaccines are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Human Combination Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now